Search research articles
Contact Us
Filters
Showing results (41-50 of 67) with videos related to
Page
of 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2020
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
Ailin Lepletier, Jason Madore, Jake S O'Donnell, et al.
Journal for Immunotherapy of Cancer
|
August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Nature Medicine
|
May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
Claus Garbe, Reinhard Dummer, Teresa Amaral, et al.
JAMA Oncology
|
March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
Lancet (London, England)
|
April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Frontiers in Oncology
|
October 12, 2020
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
Francesco Mannavola, Mario Mandala, Annalisa Todisco, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2024
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 67) with videos related to
Sort By:
Page
of 7
European Journal of Cancer (Oxford, England : 1990)
|
October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2020
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
Ailin Lepletier, Jason Madore, Jake S O'Donnell, et al.
Journal for Immunotherapy of Cancer
|
August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Nature Medicine
|
May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
Claus Garbe, Reinhard Dummer, Teresa Amaral, et al.
JAMA Oncology
|
March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
Lancet (London, England)
|
April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J Luke, Piotr Rutkowski, Paola Queirolo, et al.
The New England Journal of Medicine
|
April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
Frontiers in Oncology
|
October 12, 2020
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
Francesco Mannavola, Mario Mandala, Annalisa Todisco, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2024
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Page
of 7